Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11988668 Concentration-dependent self-interaction assay

Patent 11988668 was granted and assigned to Regeneron Pharmaceuticals on May, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Regeneron Pharmaceuticals

0

Current Assignee

Regeneron Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Michael Marlow0

Michael Sennett0

Michael Schneider0

Date of Patent

May 21, 2024

0

Patent Application Number

178689830

Date Filed

July 20, 2022

0

Patent Citations

US Patent 7771997 Enhanced expression and stability regions

0

US Patent 7087411 Fusion protein capable of binding VEGF

0

US Patent 7514938 Dielectric relaxation spectroscopy apparatus and methods of use

0

US Patent 7927583 Receptor based antagonists and methods of making and using

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

Patent abstract

Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11988668 Concentration-dependent self-interaction assay

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool